Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-6bf8c574d5-9nwgx Total loading time: 0 Render date: 2025-02-23T12:57:05.105Z Has data issue: false hasContentIssue false

Opicapone

Published online by Cambridge University Press:  20 February 2025

K. Ray Chaudhuri ,
Peter Jenner ,
Valentina Leta ,
Shelley Jones  and
Iro Boura
K. Ray Chaudhuri
Affiliation:
King's College London
Peter Jenner
Affiliation:
King's College London
Valentina Leta
Affiliation:
King's College London
Shelley Jones
Affiliation:
King's College London
Iro Boura
Affiliation:
St. George General Hospital of Chania, Crete, Greece
Get access

Summary

Opicapone (2,5-dichloro-3-[5-(3,4-dihydroxy-5-nitrophenyl)-1,2,4-oxadiazol-3-yl]-4,6-dimethylpyridine N-oxide) is a yellow powder/crystalline solid with poor aqueous solubility. It has a molecular weight of 413.2 and an empirical formula of C15H10Cl2N4O6.

Type
Chapter
Information
The Movement Disorders Prescriber's Guide to Parkinson's Disease , pp. 324 - 332
Publisher: Cambridge University Press
Print publication year: 2025

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Suggested Reading

Fabbri, M, Ferreira, JJ, Lees, A, Stocchi, F, Poewe, W, Tolosa, E, Rascol, O. Opicapone for the treatment of Parkinson’s disease: a review of a new licensed medicine. Mov Disord 2018; 33(10): 1528–1539.CrossRefGoogle Scholar
Ferreira, JJ, Lees, A, Rocha, JF, Poewe, W, Rascol, O, Soares-da-Silva, P; Bi-Park 1 Investigators. Opicapone as an adjunct to levodopa in patients with Parkinson’s disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trial. Lancet Neurol 2016; 15(2): 154–165.CrossRefGoogle Scholar
Jenner, P., Rocha, JF, Ferreira, JJ, Rascol, O, Soares-da-Silva, P. Redefining the strategy for the use of COMT inhibitors in Parkinson’s disease: the role of opicapone. Expert Rev Neurother 2021; 21(9): 1019–1033.CrossRefGoogle ScholarPubMed
Leta, V., van Wamelen, DJ, Sauerbier, A, Jones, S, Parry, M, Rizos, A, Chaudhuri, KR. Opicapone and levodopa–carbidopa intestinal gel infusion: the way forward towards cost savings for healthcare systems? J Parkinsons Dis 2020; 10(4): 1535–1539.CrossRefGoogle ScholarPubMed
Reichmann, H, Lees, A, Rocha, JF, Magalhães, D, Soares-da-Silva, P; OPTIPARK Investigators. Effectiveness and safety of opicapone in Parkinson’s disease patients with motor fluctuations: the OPTIPARK open-label study. Transl Neurodegener. 2020 Mar 4; 9(1):9. doi: 10.1186/s40035-020-00187-1.CrossRefGoogle ScholarPubMed

References

AHFS Drug information, 2012. Bethesda: American Society of Health-System Pharmacists. Accessed on 22 April 2022 via www.medicinescomplete.com.Google Scholar
Ferreira, JJ. , Poewe, W, Rascol, O, Stocchi, F, Antonini, A, Moreira, J, Guimarães, B, Rocha, JF, Soares-da-Silva, P. Effect of opicapone on levodopa pharmacokinetics in patients with fluctuating Parkinson’s disease. Mov Disord 2022; 37(11): 2272–2283.CrossRefGoogle Scholar
Joint Formulary Committee. British National Formulary (online). London: BMJ Group and Pharmaceutical Press. Accessed on 22 April 2022 via www.medicinescomplete.com.Google Scholar
Lees, AJ, Ferreira, J, Rascol, O, Poewe, W, Rocha, JF, McCrory, M, Soares-da-Silva, P. Opicapone as adjunct to levodopa therapy in patients with Parkinson disease and motor fluctuations: a randomized clinical trial. JAMA Neurol 2017; 74(2): 197–206.CrossRefGoogle ScholarPubMed
Opicapone. In: Brayfield, A (Ed.), Martindale: The Complete Drug Reference. London: The Royal Pharmaceutical Society of Great Britain. Accessed on 22 April 2022 via www.medicinescomplete.com.Google Scholar
Opicapone. In: DRUGDEX® System (electronic version). Truven Health Analytics, Greenwood Village, Colorado, USA. Accessed on 22 April 2022 via www.micromedexsolutions.com.Google Scholar
Scott, LJ. Opicapone: a review in Parkinson’s disease. CNS Drugs 2021; 35(1): 121–131.CrossRefGoogle ScholarPubMed
Summary of product characteristics – Ongentys 25 mg hard capsules. Bial Pharma UK Ltd. Electronic Medicines Compendium: Ongentys 25 mg hard capsules – summary of product characteristics (SmPC) – (emc). Accessed on 22 April 2022 via www.medicines.org.uk.Google Scholar
Takeda, A, Takahashi, R, Tsuboi, Y, Nomoto, M, Maeda, T, Nishimura, A, Yoshida, K, Hattori, N. Long-term safety and efficacy of opicapone in Japanese Parkinson’s patients with motor fluctuations. J Neural Transm (Vienna) 2021; 128(3): 337–344.CrossRefGoogle ScholarPubMed
Takeda, A, Takahashi, R, Tsuboi, Y, Nomoto, M, Maeda, T, Nishimura, A, Yoshida, K, Hattori, N. Randomized, controlled study of opicapone in Japanese Parkinson’s patients with motor fluctuations. Mov Disord 2021; 36(2): 415–423.CrossRefGoogle ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure [email protected] is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

  • Opicapone
  • K. Ray Chaudhuri, King's College London, Peter Jenner, King's College London, Valentina Leta, King's College London, Shelley Jones, King's College London, Iro Boura, St. George General Hospital of Chania, Crete, Greece
  • Book: The Movement Disorders Prescriber's Guide to Parkinson's Disease
  • Online publication: 20 February 2025
  • Chapter DOI: https://doi.org/10.1017/9781009222648.035
Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

  • Opicapone
  • K. Ray Chaudhuri, King's College London, Peter Jenner, King's College London, Valentina Leta, King's College London, Shelley Jones, King's College London, Iro Boura, St. George General Hospital of Chania, Crete, Greece
  • Book: The Movement Disorders Prescriber's Guide to Parkinson's Disease
  • Online publication: 20 February 2025
  • Chapter DOI: https://doi.org/10.1017/9781009222648.035
Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

  • Opicapone
  • K. Ray Chaudhuri, King's College London, Peter Jenner, King's College London, Valentina Leta, King's College London, Shelley Jones, King's College London, Iro Boura, St. George General Hospital of Chania, Crete, Greece
  • Book: The Movement Disorders Prescriber's Guide to Parkinson's Disease
  • Online publication: 20 February 2025
  • Chapter DOI: https://doi.org/10.1017/9781009222648.035
Available formats
×